TY - JOUR T1 - Does Vidarabine Mediate Cardioprotection via Inhibition of AC5? JF - Journal of Pharmacology and Experimental Therapeutics JO - J Pharmacol Exp Ther SP - 242 LP - 243 DO - 10.1124/jpet.116.234245 VL - 358 IS - 2 AU - Roland Seifert Y1 - 2016/08/01 UR - http://jpet.aspetjournals.org/content/358/2/242.abstract N2 - There is an ongoing discussion about the value of adenylyl cyclase 5 (AC5) as drug target for treatment of heart failure. This letter discusses statistical, pharmacokinetic, and pharmacodynamic reasons why the recently proposed cardioprotective effects of vidarabine cannot be readily attributed to AC5 inhibition. ER -